AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

Shots:

• Kyowa Kirin to receives upfront, regulatory & commercial milestones. AstraZeneca to get global rights to develop & commercialize Fasenra (beralizumab) for all indication across 14 Asian countries including Japan
• In Mar,2017 AstraZeneca & Kyowa Kirin collaborated to develop & commercialize Fasenra (beralizumab) for severe asthma and chronic obstructive pulmonary disease (COPD) in Asia
• Fasenra (beralizumab, SC, 30mg, FD) is a mAb admninistered using prefilled syringe targeting NKcells and has received FDA’s ODD for the hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA)

Click here to read full press release/ article | Ref: Kyowa Hakko Kirin | Image: Kyowa Hakko Kirin